-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Neutral on Nektar Therapeutics, Lowers Price Target to $50

Benzinga·09/23/2026 12:25:01
Wedbush analyst Martin Fan maintains Nektar Therapeutics (NASDAQ:NKTR) with a Neutral and lowers the price target from $80 to $50.